3367 related articles for article (PubMed ID: 7520681)
41. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.
Middleton MR; Lorigan P; Owen J; Ashcroft L; Lee SM; Harper P; Thatcher N
Br J Cancer; 2000 Mar; 82(6):1158-62. PubMed ID: 10735499
[TBL] [Abstract][Full Text] [Related]
42. Addition of dacarbazine or cisplatin to interferon-alpha/interleukin-2 in metastatic melanoma: toxicity and immunological effects.
Keilholz U; Scheibenbogen C; Möhler T; Brossart P; Maclachlan D; Geueke AM; Jochim A; Hunstein W
Melanoma Res; 1995 Aug; 5(4):283-7. PubMed ID: 7496166
[TBL] [Abstract][Full Text] [Related]
43. Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma.
Kivelä T; Suciu S; Hansson J; Kruit WH; Vuoristo MS; Kloke O; Gore M; Hahka-Kemppinen M; Parvinen LM; Kumpulainen E; Humblet Y; Pyrhönen S
Eur J Cancer; 2003 May; 39(8):1115-20. PubMed ID: 12736111
[TBL] [Abstract][Full Text] [Related]
44. Phase II study of interferon alpha-2a and dacarbazine in advanced melanoma.
Bajetta E; Negretti E; Giannotti B; Brogelli L; Brunetti I; Sertoli MR; Bernengo MG; Sofra MC; Maifredi G; Zumiani G
Am J Clin Oncol; 1990 Oct; 13(5):405-9. PubMed ID: 2220660
[TBL] [Abstract][Full Text] [Related]
45. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
46. Dacarbazine DTIC and carboplatin as an outpatient treatment for disseminated malignant melanoma.
Nieboer P; Mulder NH; Van Der Graaf WT; Willemse PH; Hospers GA
Anticancer Res; 2001; 21(4B):3115-6. PubMed ID: 11712820
[TBL] [Abstract][Full Text] [Related]
47. [Combination of dacarbazine, vindesine and interferon alpha in the treatment of metastatic melanoma].
Mansat-Krzyzanowska E; Dreno B
Ann Dermatol Venereol; 1994; 121(12):884-7. PubMed ID: 7632005
[TBL] [Abstract][Full Text] [Related]
48. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
O'Day SJ; Atkins MB; Boasberg P; Wang HJ; Thompson JA; Anderson CM; Gonzalez R; Lutzky J; Amatruda T; Hersh EM; Weber JS
J Clin Oncol; 2009 Dec; 27(36):6207-12. PubMed ID: 19917850
[TBL] [Abstract][Full Text] [Related]
49. [Chemotherapy of advanced stage melanoma using cisplatin, epirubicin and alpha-interferon].
Carpano S; Amodio A; Bucher S; Foggi P; Vici P; Rinaldi M; Mariotti S; Del Monte G; Lopez M
Clin Ter; 1999; 150(2):109-14. PubMed ID: 10396859
[TBL] [Abstract][Full Text] [Related]
50. Preliminary experience with high-dose cisplatin, reduced glutathione and natural interferon-alpha in dacarbazine-resistant malignant melanoma.
Bajetta E; Rimassa L; Carnaghi C; Del Vecchio M; Celio L; Cassata A
Tumori; 1998; 84(1):48-51. PubMed ID: 9619714
[TBL] [Abstract][Full Text] [Related]
51. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma.
Legha SS; Ring S; Papadopoulos N; Plager C; Chawla S; Benjamin R
Cancer; 1989 Nov; 64(10):2024-9. PubMed ID: 2804890
[TBL] [Abstract][Full Text] [Related]
52. Treatment of advanced malignant melanoma with recombinant interferon alfa-2a in combination with DTIC: long-term follow-up of two phase II studies.
Hersey P; McLeod GR; Thomson DB
Br J Haematol; 1991 Oct; 79 Suppl 1():60-6. PubMed ID: 1931712
[TBL] [Abstract][Full Text] [Related]
53. Dacarbazine (DTIC), human recombinant interferon alpha 2a (Roferon) and 5-fluorouracil for disseminated malignant melanoma.
Mulder NH; de Vries EG; Sleijfer DT; Schraffordt Koops H; Willemse PH
Br J Cancer; 1992 Feb; 65(2):303-4. PubMed ID: 1739635
[No Abstract] [Full Text] [Related]
54. A phase II study of high-dose hydroxyurea and dacarbazine (DTIC) in the treatment of metastatic malignant melanoma.
Philip PA; Carmichael J; Tonkin K; Ganesan TA; Harris AL
Eur J Cancer; 1994; 30A(7):1027-9. PubMed ID: 7946568
[TBL] [Abstract][Full Text] [Related]
55. A phase II study of metastatic melanoma treated with a combination of interferon alfa 2b, dacarbazine and nimustine.
Gröhn P; Kumpulainen E; Nuortio L; Hakala T; Vuoristo MS; Korpela M; Heikkinen M; Salmi R; Jakobsson M; Numminen S
Eur J Cancer; 1992; 28(2-3):441-3. PubMed ID: 1591060
[TBL] [Abstract][Full Text] [Related]
56. Concurrent chemoimmunotherapy: is it still the best option for the treatment of metastatic melanoma in patients with good performance status?
Pejcic I; Vrbic S; Filipovic S; Scekic M; Petkovic I; Pejcic Lj
J BUON; 2010; 15(3):470-4. PubMed ID: 20941812
[TBL] [Abstract][Full Text] [Related]
57. Dibromodulcitol (DBD), DTIC, and actinomycin-D in disseminated malignant melanoma. A phase I-II clinical trial.
Samson MK; Haas CD; Baker LH; Cummings G
Am J Clin Oncol; 1985 Apr; 8(2):167-71. PubMed ID: 3834791
[TBL] [Abstract][Full Text] [Related]
58. Controlled study of DTIC versus DTIC plus epirubicin in metastatic malignant melanoma.
Lopez M; Perno CF; Di Lauro L; Papaldo P; Ganzina F; Barduagni A
Invest New Drugs; 1984; 2(3):319-22. PubMed ID: 6392148
[TBL] [Abstract][Full Text] [Related]
59. Recombinant interferon-alpha2a plus 5-fluorouracil for the treatment of metastatic melanoma.
Walpole ET; Hersey P; Thomson D; McLeod GR
Melanoma Res; 1997 Dec; 7(6):513-6. PubMed ID: 9464625
[TBL] [Abstract][Full Text] [Related]
60. Interferon alpha-2a and dacarbazine in melanoma.
Kirkwood JM; Ernstoff MS; Giuliano A; Gams R; Robinson WA; Costanzi J; Pouillart P; Speyer J; Grimm M; Spiegel R
J Natl Cancer Inst; 1990 Jun; 82(12):1062-3. PubMed ID: 2189999
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
